Doximity, Inc. (NYSE:DOCS) is highlighted as one of the best digital health stocks to buy now. Morgan Stanley maintained an Equal-Weight rating on Doximity, with a price target of $62. Analyst Craig Hettenbach noted strong growth in the video module business, exceeding expectations in Q3. Competitive pressure concerns were addressed, with no measurable impact from OpenEvidence. The company reported Q2 FY26 revenue of $168.5 million, up 23% YoY, and adjusted EBITDA of $100.8 million. Q3 FY26 revenue guidance is $180–$181 million, with FY26 revenue projected at $640–$646 million. Doximity offers a digital platform for medical professionals, facilitating networking, telehealth, and physician marketing. While DOCS shows investment potential, other AI stocks may offer greater upside with less risk. For a potentially undervalued AI stock with growth potential, explore the best short-term AI stock.

Read more at Yahoo Finance: Morgan Stanley Stays Neutral on Doximity, Highlights Strength in Video Module Business